Licochalcone B inhibits growth of bladder cancer cells by arresting cell cycle progression and inducing apoptosis

Food and Chemical Toxicology

Volumn 65, Issue , 2014, Pages 242-251

  Yuan, Xuan ^a   Li, Tao ^a   Xiao, Erlong ^a   Zhao, Hong ^b   Li, Yongqian ^a   Fu, Shengjun ^a   Gan, Lu ^d   Wang, Zhenhua ^c   Zheng, Qiusheng ^b,c   Wang, Zhiping ^a  

^a LANZHOU UNIVERSITY   (China)

^b SHIHEZI UNIVERSITY   (China)

^c YANTAI UNIVERSITY   (China)

^d INSTITUTE OF MODERN PHYSICS   (China)

Author keywords

Apoptosis; Bladder cancer; Licochalcone B; S phase arrest

Indexed keywords

CASPASE 3; CELL CYCLE PROTEIN; CELL CYCLE PROTEIN 25A; CELL CYCLE PROTEIN 25B; CYCLIN A; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; LICOCHALCONE B; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; SURVIVIN; UNCLASSIFIED DRUG; CELL DIVISION CYCLE PROTEIN 25A; CELL DIVISION CYCLE PROTEIN 25B; PHOSPHOPROTEIN PHOSPHATASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; C57BL 6 MOUSE; CANCER CELL; CANCER INHIBITION; CANCER MODEL; CANCER PREVENTION; CARCINOGENICITY; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL DIVISION; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN EJ; CELL STRAIN MB49; CELL STRAIN T24; CHEMOPROPHYLAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; REACTION TIME; S PHASE CELL CYCLE CHECKPOINT; ANTIPROLIFERATIVE ACTIVITY; BLADDER CANCER CELL LINE; DRUG MECHANISM;

APOPTOSIS; BLADDER CANCER; LICOCHALCONE B; S PHASE ARREST;

ANIMALS; APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE, TUMOR; CHALCONES; DNA PRIMERS; HUMANS; MALE; MICE; MICE, INBRED C57BL; POLYMERASE CHAIN REACTION; URINARY BLADDER NEOPLASMS;

EID: 84892871517     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2013.12.030     Document Type: Article

References (40)

1. Adams J.M., Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998, 281(5381):1322-1326.
2. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 2003, 3(1):46-54.
3. Bremer E., van Dam G., Kroesen B.J., de Leij L., Helfrich W. Targeted induction of apoptosis for cancer therapy: current progress and prospects. Trends Mol. Med. 2006, 12(8):382-393.
4. Burlacu A. Regulation of apoptosis by Bcl-2 family proteins. J. Cell. Mol. Med. 2003, 7(3):249-257.
5. Chowdhury R., Chatterjee R., Giri A.K., Mandal C., Chaudhuri K. Arsenic-induced cell proliferation is associated with enhanced ROS generation, Erk signaling and CyclinA expression. Toxicol. Lett. 2010, 198(2):263-271.
6. Deep G., Agarwal R. New combination therapies with cell-cycle agents. Curr. Opin. Investig. Drugs 2008, 9(6):591-604.
7. Espinoza-Hicks J.C., Camacho-Davila A.A., Flores-Holguin N.R., Nevarez-Moorillon G.V., Glossman-Mitnik D., Rodriguez-Valdez L.M. Experimental and quantum chemical studies of a novel synthetic prenylated chalcone. Chem. Cent. J. 2013, 7(1):17.
8. Ferguson A.M., White L.S., Donovan P.J., Piwnica-Worms H. Normal cell cycle and checkpoint responses in mice and cells lacking Cdc25B and Cdc25C protein phosphatases. Mol. Cell. Biol. 2005, 25(7):2853-2860.
9. Gerhauser C., et al. Cancer chemopreventive activity of Xanthohumol, a natural product derived from hop. Mol. Cancer Ther. 2002, 1(11):959-969.
10. Haraguchi H., Tanimoto K., Tamura Y., Mizutani K., Kinoshita T. Mode of antibacterial action of retrochalcones from Glycyrrhiza inflata. Phytochemistry 1998, 48(1):125-129.
11. Herr H.W., Laudone V.P., Whitmore W.F. An overview of intravesical therapy for superficial bladder tumors. J. Urol. 1987, 138(6):1363-1368.
12. Hockenbery D., Nunez G., Milliman C., Schreiber R.D., Korsmeyer S.J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990, 348(6299):334-336.
13. Hoffmann I., Draetta G., Karsenti E. Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J. 1994, 13(18):4302-4310.
14. Hou J., Wang D., Zhang R., Wang H. Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2008, 14(17):5519-5530.
15. Hseu Y.C., Lee M.S., Wu C.R., Cho H.J., Lin K.Y., Lai G.H., Wang S.Y., Kuo Y.H., Kumar K.J., Yang H.L. The chalcone flavokawain B induces G2/M cell-cycle arrest and apoptosis in human oral carcinoma HSC-3 cells through the intracellular ROS generation and downregulation of the Akt/p38 MAPK signaling pathway. J. Agric. Food Chem. 2012, 60(9):2385-2397.
16. Huncharek M., McGarry R., Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res. 2001, 21(1B):765-769.
17. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics, 2007. CA: A Cancer J. Clin. 2007, 57(1):43-66.
18. Ji T., Lin C., Krill L.S., Eskander R., Guo Y., Zi X., Hoang B.H. Flavokawain B, a kava chalcone, inhibits growth of human osteosarcoma cells through G2/M cell cycle arrest and apoptosis. Mol. Cancer 2013, 12:55.
19. Johnson D.G., Walker C.L. Cyclins and cell cycle checkpoints. Annu. Rev. Pharmacol. Toxicol. 1999, 39:295-312.
20. Jung J.I., Lim S.S., Choi H.J., Cho H.J., Shin H.K., Kim E.J., Chung W.Y., Park K.K., Park J.H. Isoliquiritigenin induces apoptosis by depolarizing mitochondrial membranes in prostate cancer cells. J. Nutr. Biochem. 2006, 17(10):689-696.
21. Kiyokawa H., Ray D. In vivo roles of CDC25 phosphatases: biological insight into the anti-cancer therapeutic targets. Anticancer Agents Med. Chem. 2008, 8(8):832-836.
22. Lammer C., Wagerer S., Saffrich R., Mertens D., Ansorge W., Hoffmann I. The cdc25B phosphatase is essential for the G2/M phase transition in human cells. J. Cell. Sci. 1998, 111(Pt 16):2445-2453.
23. Lawen A. Apoptosis-an introduction. Bioessays 2003, 25(9):888-896.
24. Lee S.J., Lee E.J., Kim S.K., Jeong P., Cho Y.H., Yun S.J., Kim S., Kim G.Y., Choi Y.H., Cha E.J., Kim W.J., Moon S.K. Identification of pro-inflammatory cytokines associated with muscle invasive bladder cancer; the roles of IL-5, IL-20, and IL-28A. PloS One 2012, 7(9):e40267.
25. Ma L., Feugang J.M., Konarski P., Wang J., Lu J., Fu S., Ma B., Tian B., Zou C., Wang Z. Growth inhibitory effects of quercetin on bladder cancer cell. Front Biosci. 2006, 11:2275-2285.
26. Park M.T., Lee S.J. Cell cycle and cancer. J. Biochem. Mol. Biol. 2003, 36(1):60-65.
27. Pichu S., Krishnamoorthy S., Shishkov A., Zhang B., McCue P., Ponnappa B.C. Knockdown of Ki-67 by dicer-substrate small interfering RNA sensitizes bladder cancer cells to curcumin-induced tumor inhibition. PloS One 2012, 7(11):e48567.
28. Rao Y.K., Kao T.Y., Ko J.L., Tzeng Y.M. Chalcone HTMC causes in vitro selective cytotoxicity, cell-cycle G1 phase arrest through p53-dependent pathway in human lung adenocarcinoma A549 cells, and in vivo tumor growth suppression. Bioorg. Med. Chem. Lett. 2010, 20(22):6508-6512.
29. Riedl S.J., Renatus M., Schwarzenbacher R., Zhou Q., Sun C., Fesik S.W., Liddington R.C., Salvesen G.S. Structural basis for the inhibition of caspase-3 by XIAP. Cell 2001, 104(5):791-800.
30. Samuelsson M.K., Pazirandeh A., Davani B., Okret S. P57Kip2, a glucocorticoid-induced inhibitor of cell cycle progression in HeLa cells. Mol. Endocrinol. 1999, 13(11):1811-1822.
31. Sawle P., Moulton B.E., Jarzykowska M., Green C.J., Foresti R., Fairlamb I.J., Motterlini R. Structure-activity relationships of methoxychalcones as inducers of heme oxygenase-1. Chem. Res. Toxicol. 2008, 21(7):1484-1494.
32. Shen Z., Shen T., Wientjes M.G., O'Donnell M.A., Au J.L. Intravesical treatments of bladder cancer: review. Pharmaceut. Res. 2008, 25(7):1500-1510.
33. Slee E.A., Adrain C., Martin S.J. Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J. Biol. Chem. 2001, 276(10):7320-7326.
34. Sun C., Zhang H., Ma X.F., Zhou X., Gan L., Liu Y.Y., Wang Z.H. Isoliquiritigenin enhances radiosensitivity of HepG2 cells via disturbance of redox status. Cell Biochem. Biophys. 2013, 65(3):433-444.
35. Tan W., et al. Anti-cancer natural products isolated from Chinese medicinal herbs. Chin. Med. 2011, 6(1):27.
36. Tang Y., Simoneau A.R., Xie J., Shahandeh B., Zi X. Effects of the kava chalcone flavokawain A differ in bladder cancer cells with wild-type versus mutant p53. Cancer Prev. Res. (Phila) 2008, 1(6):439-451.
37. Tian B., et al. Effects of curcumin on bladder cancer cells and development of urothelial tumors in a rat bladder carcinogenesis model. Cancer Lett. 2008, 264(2):299-308.
38. Unger C., et al. An apolar extract of Critonia morifolia inhibits c-Myc, cyclin D1, Cdc25A, Cdc25B, Cdc25C and Akt and induces apoptosis. Int. J. Oncol. 2012, 40(6):2131-2139.
39. Zhou J.R., Mukherjee P., Gugger E.T., Tanaka T., Blackburn G.L., Clinton S.K. Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis. Cancer Res. 1998, 58(22):5231-5238.
40. Zi X., Simoneau A.R. Flavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice. Cancer Res. 2005, 65(8):3479-3486.